JP2021502337A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502337A5 JP2021502337A5 JP2020524284A JP2020524284A JP2021502337A5 JP 2021502337 A5 JP2021502337 A5 JP 2021502337A5 JP 2020524284 A JP2020524284 A JP 2020524284A JP 2020524284 A JP2020524284 A JP 2020524284A JP 2021502337 A5 JP2021502337 A5 JP 2021502337A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- optionally
- water
- dichlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 52
- DEOUZFWSQWEPGE-UHFFFAOYSA-N 2-methylheptanamide Chemical compound CCCCCC(C)C(N)=O DEOUZFWSQWEPGE-UHFFFAOYSA-N 0.000 claims description 14
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 14
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 12
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 229920001400 block copolymer Polymers 0.000 claims description 10
- 229920001992 poloxamer 407 Polymers 0.000 claims description 10
- 229940044476 poloxamer 407 Drugs 0.000 claims description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- 239000007900 aqueous suspension Substances 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- HNLJEOAFXYIQQM-UHFFFAOYSA-N N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound ClC=1C=C(C=CC=1Cl)NC(=O)C1C2CCC(C1C1=CC=NC=C1)O2 HNLJEOAFXYIQQM-UHFFFAOYSA-N 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 206010060820 Joint injury Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 229920001993 poloxamer 188 Polymers 0.000 claims description 4
- 229940044519 poloxamer 188 Drugs 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- -1 pyridine-4-yl Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584589P | 2017-11-10 | 2017-11-10 | |
| US62/584,589 | 2017-11-10 | ||
| US201862743864P | 2018-10-10 | 2018-10-10 | |
| US62/743,864 | 2018-10-10 | ||
| PCT/IB2018/058788 WO2019092637A1 (en) | 2017-11-10 | 2018-11-08 | Extended release formulations for intra-articular applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502337A JP2021502337A (ja) | 2021-01-28 |
| JP2021502337A5 true JP2021502337A5 (enExample) | 2021-12-09 |
| JP7284750B2 JP7284750B2 (ja) | 2023-05-31 |
Family
ID=64402238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524284A Active JP7284750B2 (ja) | 2017-11-10 | 2018-11-08 | 関節内適用のための持続放出製剤 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20210177824A1 (enExample) |
| EP (1) | EP3706710B1 (enExample) |
| JP (1) | JP7284750B2 (enExample) |
| KR (1) | KR20200087138A (enExample) |
| CN (1) | CN111278410A (enExample) |
| AU (1) | AU2018364685B2 (enExample) |
| CA (1) | CA3075722A1 (enExample) |
| CL (1) | CL2020001156A1 (enExample) |
| DK (1) | DK3706710T3 (enExample) |
| ES (1) | ES2981903T3 (enExample) |
| FI (1) | FI3706710T3 (enExample) |
| HR (1) | HRP20240808T1 (enExample) |
| HU (1) | HUE066971T2 (enExample) |
| IL (2) | IL274149B2 (enExample) |
| LT (1) | LT3706710T (enExample) |
| MX (2) | MX2020004477A (enExample) |
| PL (1) | PL3706710T3 (enExample) |
| PT (1) | PT3706710T (enExample) |
| RS (1) | RS65659B1 (enExample) |
| SA (1) | SA520411881B1 (enExample) |
| SI (1) | SI3706710T1 (enExample) |
| TW (2) | TWI813597B (enExample) |
| WO (1) | WO2019092637A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020115683A1 (en) * | 2018-12-06 | 2020-06-11 | Novartis Ag | 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage |
| KR20220076371A (ko) * | 2020-11-30 | 2022-06-08 | 주식회사 엘지화학 | 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법 |
| KR20240133027A (ko) | 2023-02-28 | 2024-09-04 | 주식회사 포스테라헬스사이언스 | 올리고펩타이드를 포함하는 서방형 입자 및 이의 제조 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI527590B (zh) * | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Ｆｇｆ－１８之凍乾調配物 |
| MX377796B (es) * | 2014-05-13 | 2025-03-11 | Novartis Ag | Compuestos y composiciones para inducir condrogenesis. |
-
2018
- 2018-11-08 TW TW107139598A patent/TWI813597B/zh active
- 2018-11-08 EP EP18807130.2A patent/EP3706710B1/en active Active
- 2018-11-08 HR HRP20240808TT patent/HRP20240808T1/hr unknown
- 2018-11-08 PT PT188071302T patent/PT3706710T/pt unknown
- 2018-11-08 HU HUE18807130A patent/HUE066971T2/hu unknown
- 2018-11-08 TW TW112133215A patent/TW202400164A/zh unknown
- 2018-11-08 FI FIEP18807130.2T patent/FI3706710T3/fi active
- 2018-11-08 AU AU2018364685A patent/AU2018364685B2/en active Active
- 2018-11-08 ES ES18807130T patent/ES2981903T3/es active Active
- 2018-11-08 DK DK18807130.2T patent/DK3706710T3/da active
- 2018-11-08 IL IL274149A patent/IL274149B2/en unknown
- 2018-11-08 RS RS20240689A patent/RS65659B1/sr unknown
- 2018-11-08 CN CN201880070509.XA patent/CN111278410A/zh active Pending
- 2018-11-08 JP JP2020524284A patent/JP7284750B2/ja active Active
- 2018-11-08 MX MX2020004477A patent/MX2020004477A/es unknown
- 2018-11-08 CA CA3075722A patent/CA3075722A1/en active Pending
- 2018-11-08 WO PCT/IB2018/058788 patent/WO2019092637A1/en not_active Ceased
- 2018-11-08 KR KR1020207012904A patent/KR20200087138A/ko active Pending
- 2018-11-08 US US16/761,779 patent/US20210177824A1/en not_active Abandoned
- 2018-11-08 PL PL18807130.2T patent/PL3706710T3/pl unknown
- 2018-11-08 IL IL305541A patent/IL305541A/en unknown
- 2018-11-08 SI SI201831112T patent/SI3706710T1/sl unknown
- 2018-11-08 LT LTEPPCT/IB2018/058788T patent/LT3706710T/lt unknown
-
2020
- 2020-04-30 SA SA520411881A patent/SA520411881B1/ar unknown
- 2020-05-04 CL CL2020001156A patent/CL2020001156A1/es unknown
- 2020-07-13 MX MX2023007036A patent/MX2023007036A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI492769B (zh) | 可注射的水性眼用組成物及其使用之方法 | |
| JP2013534244A5 (enExample) | ||
| TWI789448B (zh) | 灰指甲治療用之外用製劑 | |
| JP2021502337A5 (enExample) | ||
| CN119546278A (zh) | 两性离子在眼用局部乳膏组合物和制剂中的新应用 | |
| JP2011513492A5 (enExample) | ||
| RU2010141542A (ru) | Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций | |
| JP2009544665A5 (enExample) | ||
| JP2015007136A5 (enExample) | ||
| JP2015110672A (ja) | ビマトプロストおよびブリモニジンの固定用量の組み合わせ | |
| JP2020511443A5 (enExample) | ||
| JP2003509351A5 (enExample) | ||
| JP2018532806A5 (enExample) | ||
| WO2008020096A1 (es) | Composición farmacéutica con promotores de absorción | |
| US11517571B2 (en) | Use of kinase inhibitors to manage tuberculosis and other infectious diseases | |
| JP2006521362A (ja) | 保存眼科用組成物 | |
| RU2020131402A (ru) | 4-метилдигидропиримидиноновые соединения и их применение в фармацевтике | |
| WO2006132342A1 (ja) | ロフルミラスト点眼液 | |
| FI3706710T3 (fi) | Pitkäkestoisesti vapautuvia formulaatioita nivelensisäisiin käyttötarkoituksiin | |
| JP5922609B2 (ja) | ２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸含有水性組成物 | |
| US11510985B2 (en) | Oral composition for delivery of drugs and other substances | |
| JP2005247821A (ja) | 炎症性サイトカインの産生を抑制するための眼科用組成物 | |
| JPH1192368A (ja) | ベンゾピラン誘導体を主成分とする水性液剤 | |
| JP2018527345A (ja) | ポリマーおよびその使用方法 | |
| RU2018123711A (ru) | Композиции для внутривенного введения |